延迟给予BTB09089靶向神经元GPR65改善缺血性卒中后的神经康复
研究在光血栓性缺血野生型与GPR65敲除小鼠中,于卒中后第3、7或14天隔日腹腔注射GPR65激动剂BTB09089,发现其经激活神经元GPR65促进运动功能恢复与脑组织修复,过表达GPR65可将治疗时间窗延至第14天。
要点
- BTB09089延迟3至7天给药仍显著改善野生型小鼠运动结局,GPR65敲除小鼠中无效。
- BTB09089抑制野生型小鼠小胶质细胞活化与胶质瘢痕进展,减少神经元密度下降。
- 在梗死周围皮质神经元过表达GPR65可将BTB09089治疗时间窗延长至第14天。
核心结论
- 延迟BTB09089治疗通过激活神经元GPR65改善卒中后神经功能恢复与脑组织修复。
- 过表达GPR65可能是扩大GPR65激动剂用于缺血性卒中后神经康复治疗时间窗的潜在策略。
研究设计与样本
- 野生型与GPR65敲除小鼠经光血栓性缺血诱导缺血性卒中。
- 雄性小鼠于卒中后第3、7或14天隔日腹腔注射BTB09089。
- 采用AAV-Syn-GPR65在GPR65敲除与野生型小鼠梗死周围皮质神经元过表达GPR65。
- 以网格行走与圆柱试验监测运动功能,并通过免疫组化、Golgi-Cox染色与蛋白质印迹观察神经修复效应。
主要发现
- BTB09089显著促进野生型小鼠运动结局,但在GPR65敲除小鼠中不促进,即使延迟3至7天给药亦然。
- BTB09089抑制野生型小鼠小胶质细胞活化与胶质瘢痕进展,但在GPR65敲除小鼠中不抑制。
- BTB09089减少野生型小鼠神经元密度下降,该获益在GPR65敲除小鼠中消失,在梗死周围皮质神经元过表达GPR65后重新出现。
- 在GPR65敲除小鼠梗死周围皮质神经元过表达GPR65时,BTB09089增加GAP43与突触素斑点密度、树突棘密度、树突分支长度与树突复杂性,并伴p-CREB水平升高。
- 在野生型小鼠梗死周围皮质神经元过表达GPR65可将BTB09089治疗时间窗延长至第14天。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: GPR65 (G protein-coupled receptor 65) can sense extracellular acidic environment to regulate pathophysiological processes. Pretreatment with the GPR65 agonist BTB09089 has been proven to produce neuroprotection in acute ischemic stroke. However, whether delayed BTB09089 treatment and neuronal GPR65 activation promote neurorestoration remains unknown. METHODS: Ischemic stroke was induced in wild-type (WT) or GPR65 knockout (GPR65-/-) mice by photothrombotic ischemia. Male mice were injected intraperitoneally with BTB09089 every other day at days 3, 7, or 14 poststroke. AAV-Syn-GPR65 (adenoassociated virus-synapsin-GPR65) was utilized to overexpress GPR65 in the peri-infarct cortical neurons of GPR65-/- and WT mice. Motor function was monitored by grid-walk and cylinder tests. The neurorestorative effects of BTB09089 were observed by immunohistochemistry, Golgi-Cox staining, and Western blotting. RESULTS: BTB09089 significantly promoted motor outcomes in WT but not in GPR65-/- mice, even when BTB09089 was delayed for 3 to 7 days. BTB09089 inhibited the activation of microglia and glial scar progression in WT but not in GPR65-/- mice. Meanwhile, BTB09089 reduced the decrease in neuronal density in WT mice, but this benefit was abolished in GPR65-/- mice and reemerged by overexpressing GPR65 in peri-infarct cortical neurons. Furthermore, BTB09089 increased the GAP43 (growth-associated protein-43) and synaptophysin puncta density, dendritic spine density, dendritic branch length, and dendritic complexity by overexpressing GPR65 in the peri-infarct cortical neurons of GPR65-/- mice, which was accompanied by increased levels of p-CREB (phosphorylated cAMP-responsive element-binding protein). In addition, the therapeutic window of BTB09089 was extended to day 14 by overexpressing GPR65 in the peri-infarct cortical neurons of WT mice. CONCLUSIONS: Our findings indicated that delayed BTB09089 treatment improved neurological functional recovery and brain tissue repair poststroke through activating neuronal GRP65. GPR65 overexpression may be a potential strategy to expand the therapeutic time window of GPR65 agonists for neurorehabilitation after ischemic stroke.
引用
- Chen R, Zhang MQ, Miao YL, et al. Targeting Neuronal GPR65 With Delayed BTB09089 Treatment Improves Neurorehabilitation Following Ischemic Stroke. Stroke. 2024. PMID: 38946544. doi:10.1161/STROKEAHA.124.046954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。